Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, preventing implanting centers from billing for procedures [4]. - An excess inventory of the older Inspire IV device created a channel glut, negatively impacting demand for the new Inspire V product and leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a $42.04 per share drop in stock value, equating to a 32.4% decline [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman to discuss their legal rights before the Lead Plaintiff Deadline of January 5, 2026 [2][3]. - Hagens Berman is focusing on the concealment of critical operational issues, emphasizing the impact of management's narrative on the stock's performance [5]. - Whistleblowers with non-public information regarding Inspire are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [6].

Core Viewpoint - A class action securities lawsuit has been filed against Blue Owl Capital Inc. due to alleged securities fraud affecting investors between February 6, 2025, and November 16, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that Blue Owl Capital Inc. faced significant pressure on its asset base from redemptions by business development companies, leading to undisclosed liquidity issues [2]. - It is claimed that the company was likely to limit or halt redemptions of certain business development companies, which contradicts the positive statements made by the defendants regarding the company's business and prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until February 2, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - MoonLake Immunotherapeutics is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding its clinical data and the efficacy of its investigational drug sonelokimab [1][3][4]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a higher clinical response for patients, suggesting a competitive advantage over traditional monoclonal antibody treatments [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the Phase 3 VELA trials, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [7].

Core Viewpoint - Jefferies Financial Group Inc. and its trade finance arm, Point Bonita Capital, are under investigation for potential violations of federal securities laws following a significant exposure to First Brands Group, which filed for bankruptcy in September 2025 [1][3][5]. Group 1: Investigation Details - The SEC is probing whether Jefferies provided adequate information to investors regarding their exposure to First Brands, which had $12 billion in debt at the time of its bankruptcy [5]. - Bleichmar Fonti & Auld LLP is investigating if Jefferies and Point Bonita made materially false and misleading statements to investors concerning their exposure to First Brands [6]. Group 2: Financial Impact - On October 8, 2025, Jefferies disclosed approximately $715 million in exposure to First Brands' receivables, representing about 25% of Point Bonita's trade finance portfolio, leading to an 8% drop in Jefferies' stock price from $59.10 to $54.44 per share [4]. - Investors are reportedly seeking redemptions from Point Bonita due to the financial fallout from First Brands' bankruptcy [4].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for securities fraud, following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock [3]. - Investors have until December 23, 2025, to request to be appointed to lead the case [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations and Stock Performance - The complaint alleges that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, claiming that sales were driven by sustainable customer demand rather than inventory loading by channel partners [5]. - On August 19, 2025, James Hardie reported a 12% decline in North American fiber cement sales, leading to a stock price drop of over 34%, from $28.43 to $18.64 per share [6]. Group 4: Management Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO [7].

LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors of the upcoming January 30, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired DeFi Technologies Inc. ("DeFi" or the “Company") (NASDAQ: DEFT) securities between May 12, 2025 and November 14, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON DEFI (DEFT), CLICK HERE TO PARTICIPATE IN THE SECURITIES F ...

Core Viewpoint - A class action lawsuit has been filed against Bitdeer Technologies Group for allegedly misleading investors regarding its financial performance and the development of its next-generation ASIC chip [1][5]. Financial Performance - On November 10, 2025, Bitdeer reported a per-share loss of $1.28 for Q3 2025, significantly worse than the expected loss of $0.22 [3]. - Following the announcement, Bitdeer's stock price dropped by $2.63, or 14.90%, closing at $15.02 per share on November 11, 2025 [4]. Lawsuit Details - The lawsuit claims that Bitdeer made materially false and misleading statements throughout the class period, failing to disclose significant adverse facts about its business and operations [5]. - Specifically, the complaint highlights that the development of the SEAL04 chip, which was expected to have a chip-level energy efficiency of 5 J/TH, faced substantial delays, contradicting earlier positive statements made by the company [5].

Core Viewpoint - Blue Owl Capital Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed liquidity issues that have negatively impacted investors during the Class Period from February 6, 2025, to November 16, 2025 [1][4]. Group 1: Company Actions and Events - On November 16, 2025, it was reported that Blue Owl has blocked redemptions in one of its private credit funds as it merges with a larger vehicle, potentially leading to significant losses for investors [2]. - Following the announcement of the merger, investors in Blue Owl Capital Corporation II will lose the ability to redeem cash at the fund's Net Asset Value (NAV) and will instead exchange their shares for publicly traded Blue Owl shares, which are currently trading approximately 20% below the fund's NAV [3]. - The stock price of Blue Owl fell by as much as 6% during intraday trading on November 17, 2025, indicating a negative market reaction to the news [3]. Group 2: Legal Proceedings - The class action lawsuit alleges that Blue Owl's management made materially false and misleading statements and failed to disclose critical information regarding the company's asset base and liquidity issues [4]. - The lawsuit claims that the company was under pressure from Business Development Company (BDC) redemptions, which led to undisclosed liquidity problems and the likelihood of limiting or halting redemptions [4]. - Investors who purchased Blue Owl securities during the Class Period have until February 2, 2026, to file a lead plaintiff motion in the class action lawsuit [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Bitdeer Technologies Group securities between June 6, 2024, and November 10, 2025, due to alleged misleading statements regarding the company's SEALMINER Bitcoin mining machine [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Bitdeer provided investors with positive information about its SEALMINER A4 rigs and their expected energy efficiency of 5 J/TH while failing to disclose critical facts about the project's true state [5][6]. - Defendants allegedly made false statements that led to investors purchasing Bitdeer securities at artificially inflated prices, resulting in damages when the true information became public [6]. Group 2: Participation Information - Investors who purchased Bitdeer securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

Core Viewpoint - The lawsuit against Perrigo Company plc alleges that the company made materially false statements and failed to disclose significant issues regarding its infant formula business, leading to overstated financial results [3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Perrigo securities from February 27, 2023, to November 4, 2025, alleging misleading statements about the infant formula business [3]. - Specific allegations include underinvestment in maintenance and operational improvements, the need for substantial capital expenditures beyond stated estimates, and significant manufacturing deficiencies [3]. Group 2: Financial Impact - On November 5, 2025, Perrigo reported its third-quarter financial results and lowered its full-year guidance due to poor OTC consumption and issues with the infant formula business [4]. - Following this announcement, Perrigo's share price dropped by $5.09, approximately 25.2%, from $20.19 to $15.10 [4].